Reviewer's report

**Title:** PDGFRalpha/beta AND VEGFR2 polymorphisms in colorectal cancer: Incidence and implications in clinical outcome

**Version:** 2 Date: 22 August 2012

**Reviewer:** Takumi Ochiai

**Reviewer's report:**

**Major Compulsory Revisions**

Author should clarify differences of the oncological therapies between WT and SNP in PDGFR B19 and PDGFR B19.

If author are unable to clarify differences of the oncological therapies between WT and SNP in PDGFR B19 and PDGFR B19, author should not describe the relationship between PDGFR#/PDGFR# genetic variants and colon cancer survival.

P17, l: 17-19

"In this study, response rates were significantly higher in patients homozygous for the A-allele (AA) than in patients with the C-allele genotype (CC or CA) (56% vs 39%, p=0.015)."

Author should clarify the evidences mentioned above in Methods and Result sections.

**Minor Essential Revisions**

p2 (abstract)

l: 12

c.2439+58C>A) => c.2439+58C>A

l:13


p14 (discussion)

l:9

a significant => a substantial

**Level of interest:** An article of importance in its field

**Quality of written English:** Needs some language corrections before being published
**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests